Floatz logo

Dc-Cik

Advanced Kidney Cancer

Fuda Cancer Hospital, GuangzhouCell therapyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Advanced Kidney Cancer cohort.

Asset / SponsorPhaseRating
Guadecitabine
Ajjai Alva, MD
Phase 1/2CCC
BLOOD, WHOLE
Institute of Oncology Ljubljana
N/AD

Same molecule, other indications

Dc-Cik is also rated in:

Postoperative ComplicationsDormant
BB
Indicative ·
67 / 100
View asset →
Cytokine-induced Killer CellsDormant
BB
Indicative ·
67 / 100
View asset →
Multiple Drug UseDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →